Amendment dated November 19, 2004 Reply to Office Action of May 20, 2004

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Amended) The use of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt hydrate or solvate thereof in the preparation of an antibacterial composition

$$\begin{array}{c|c}
 & OH & R_2 \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & &$$

wherein R_2 represents a substituted or unsubstituted C_4 - C_6 -alkyl, eyeloalkyl (C_4 - C_6 -alkyl), or aryl(C_4 - C_6 -alkyl)-group, and A represents a group of formula (IA), or (IB):

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ &$$

wherein R_4 -represents the side chain of a natural or non-natural alpha amino acid, and R_5 -and R_6 are each independently hydrogen or C_4 - C_6 -alkyl, heterocyclic or aryl (C_4 - C_6 -alkyl), or R_5 -and R_6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring, characterised in that the said compound is \underline{A} method of

Amendment dated November 19, 2004

Reply to Office Action of May 20, 2004

treating bacterial infections in humans and non-human mammals comprising administering an antibacterially effective amount of a compound selected from the group consisting of

N-[3S-(4-benzylpiperidine-1-carbonyl)-2, 2-dimethyl-propyl]-3-cyclopentyl-2R [(formyl-hydroxy-amino)-methyl]-propionamide,

N-[2R-(4-benzyl-piperidine-1-carbonyl)-hexyl]-N-hydroxy-formamide,

N-hydroxy-N-[2R-(2-methyl-piperidine-1-carbonyl)-hexyl]-formamide,

N-hydroxy-N-[2R-(piperidine-1-carbonyl)-hexyl]-formamide,

N-hydroxy-N-[2R-(piperazine-1-carbonyl)-hexyl]-formamide,

2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid pyrrolidin-1-ylamide,

2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid methyl-(1-methylpiperidin-4-yl)-amide,

N-[2R-(azepane-1-carbonyl)-hexyl]-N-hydroxy-formamide,

2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid (4-methyl-piperazin-1-yl)- amide,

2R-[(formyl-hydroxy-amino)-methy]-hexanoic acid diisopropylamide,

1-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-piperidine-3-carboxylic acid ethyl ester,

4-{2 R-[(formyl-hyd roxy-amino)-methyl]-hexanoyl}-piperazine-1-carboxylic acid ethyl ester,

Amendment dated November 19, 2004 Reply to Office Action of May 20, 2004

4-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-1,1-dimethyl-piperazinium iodide,

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1 (piperidine-1-carbonyl)-propyl]-amide,

2R-[(formyl-hydroxy-amino)-methyl]-hexanoicacid [1S-(3, 4-dihydro-1*H*-isoquinoline-2-carbonyl)-2, 2-dimethyl-propyl]-amide,

2R- [(formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(4-benzyl-4-hydroxy-piperidine-1-carbonyl)-2, 2-dimethyl-propyl]-amide,

2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(4-benzyl-piperazine-1-carbonyl)-2, 2-dimethyl-propyl]-amide,

2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid (3-benzylsulfanyl-1S- dimethylcarbamoyl-propyl)-amide,

3S-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoylamino}-*N,N*-dimethyl-succinamic acid benzyl ester,

4S-dimethylcarbamoyl-4-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoyamino-butyric acid benzyl ester,

(5S-dimethylcarbamoyl-5-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoylamino}-pentyl)-dimethyl-ammonium chloride,

Amendment dated November 19, 2004

Reply to Office Action of May 20, 2004

2R-[(formyl-hydroxy-amino)-methyl]-butyric acid (1-carbamoyl-2,2-dimethylpropyl) amide,

2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid (1-carbamoyl-2,2-dimethylpropyl) amide,

2R-[formyl-hydroxy-amino)-methyl]-hexanoic acid (1-dimethyl-carbamoyl-4-guanidinobutyl)amide,

2R-[2-(4-chlorophenyl)-3- (formyl-hydroxy-amino)-propionylamino]-2S-3,3,N,N-tetramethylbutyramide,

2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [2 (3, 4-dihydroxy-phenyl)-ethyl]-amide,

2R- [(formyl-hydroxy-amino)-methyl]-hexanoic acid [2(4-hydroxyphenyl)-ethyl]-amide, andor

pharmacetically pharmaceutically and veterinarily acceptable salts, hydrates and or solvates thereof.

- 2. Canceled.
- 3. A method for the treatment of bacterial contamination by applying an antibacterially effective amount of a The method of claim 1 wherein the compound as specified in claim 1 is applied to the site of contamination;
- 4. Canceled.